Preclinical evidence on the potential of silibinin in liver cancer therapy

Main Article Content

A. Geamantan
I. Marcovici
I. Macasoi
C. Dehelean

Abstract

Liver cancer is a public health problem worldwide, hepatocellular carcinoma (HCC) constituting 90% of cases. Although research is in continuous development, the prognosis of this type of cancer remains unfavorable, as selective treatments with low toxicity are necessary. Silibinin is a flavonoid recognized for its hepatoprotective effect, antioxidant and anti-inflammatory properties, and also for its proven effectiveness in cancer treatment when administered indiviadually or in association with conventional therapies.

Article Details

Section
Articles